Pulmonary Arterial Hypertension Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Pulmonary Arterial Hypertension stocks.

Pulmonary Arterial Hypertension Stocks Recent News

Date Stock Title
Nov 21 LLY Eli Lilly, Verge announce milestones in ALS collaboration
Nov 21 LLY Eli Lilly and 2 More Drug Stocks to Buy After RFK-Inspired Drop
Nov 20 LLY Jim Cramer on Eli Lilly and Company (LLY): ‘I’m Kind Of Blown Away’
Nov 20 LLY Eli Lilly in pact with Chinese biotech for novel weight loss therapy
Nov 20 GILD Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Nov 20 LLY More companies covering weight loss drugs for their employees
Nov 20 LLY Weight loss drug makers want more insurance plans to cover Wegovy and Zepbound
Nov 20 LLY China-based biotech Laekna teams up with Lilly to develop muscle preserving obesity drug
Nov 20 UTHR Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Nov 20 LLY Eli Lilly Option Trade Produces $1,125, If You Can Tolerate The Heavy Risk
Nov 20 LLY Is It Time to Sell Eli Lilly and Pfizer Stocks?
Nov 20 LLY Verge Genomics Announces Milestones in Collaboration with Lilly to Discover and Develop Novel Treatments for ALS
Nov 20 LLY The Zacks Analyst Blog Highlights Eli Lilly, PepsiCo and Morgan Stanley
Nov 20 LLY RFK Jr. Sparks New Worries About Obesity Drugs. Here’s What Investors Should Focus on Instead.
Nov 19 LLY Lilly announces changes on board of directors
Nov 19 LLY Top Research Reports for Eli Lilly, PepsiCo & Morgan Stanley
Nov 19 LLY LLY Oral Cholesterol Drug Lowers Lipoprotein Levels in Phase II Study
Nov 19 LLY Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?
Nov 19 LLY Eli Lilly's Investigational Drug Cuts Sticky Cholesterol Levels By Almost 86%
Nov 19 LLY Jim Cramer: Coinbase Is A 'Winner,' Suggests Buying This 'Hated' Big Pharma Stock
Pulmonary Arterial Hypertension

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure within the arteries of the lungs. Symptoms include shortness of breath, syncope, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.The cause is often unknown. Risk factors include a family history, prior blood clots in the lungs, HIV/AIDS, sickle cell disease, cocaine use, COPD, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation of the arteries in the lungs. Diagnosis involves first ruling out other potential causes.There is no cure. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit clotting may be used. Medications specifically for the condition include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil. A lung transplant may be an option in certain cases.While the exact frequency of the condition is unknown, it is estimated that about 1,000 new cases occur a year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. It was first identified by Ernst von Romberg in 1891.

Browse All Tags